廣告
香港股市 已收市

  • 恒指

    17,763.03
    +16.12 (+0.09%)
     

  • 國指

    6,273.75
    -9.11 (-0.14%)
     

  • 上證綜指

    3,104.82
    -8.22 (-0.26%)
     

  • 滬深300

    3,604.39
    -19.52 (-0.54%)
     

  • 美元

    7.8227
    -0.0018 (-0.02%)
     

  • 人民幣

    0.9252
    +0.0016 (+0.17%)
     

  • 道指

    37,937.83
    -448.26 (-1.17%)
     

  • 標普 500

    5,062.18
    -53.99 (-1.06%)
     

  • 納指

    15,784.40
    -198.68 (-1.24%)
     

  • 日圓

    0.0494
    -0.0005 (-0.92%)
     

  • 歐元

    8.3505
    -0.0375 (-0.45%)
     

  • 英鎊

    9.7780
    -0.0500 (-0.51%)
     

  • 紐約期油

    81.67
    -0.96 (-1.16%)
     

  • 金價

    2,303.30
    -54.40 (-2.31%)
     

  • Bitcoin

    60,029.90
    -2,706.88 (-4.31%)
     

  • CMC Crypto 200

    1,280.08
    -58.99 (-4.41%)
     

Are You a Growth Investor? This 1 Stock Could Be the Perfect Pick

Zacks Equity Research
·2 分鐘文章

It doesn't matter your age or experience: taking full advantage of the stock market and investing with confidence are common goals for all investors.

Achieving those goals is made easier with the Zacks Style Scores, a unique set of guidelines that rates stocks based on popular investing methodologies, namely value, growth, and momentum. The Style Scores can help you narrow down which stocks are better for your portfolio and which ones can beat the market over the long-term.

Why This 1 Growth Stock Should Be On Your Watchlist

Different than value or momentum investors, growth-oriented investors are concerned with a stock's future prospects, and the overall financial health and strength of a company. Thus, they'll want to focus on the Growth Style Score, which analyzes characteristics like projected and historical earnings, sales, and cash flow to find stocks that will see sustainable growth over time.

廣告

Halozyme Therapeutics (HALO)

San Diego, CA-based Halozyme Therapeutics is a biopharmaceutical company, focused on the development and commercialization of novel treatments for oncology indications by targeting tumor microenvironment. The company also licenses its novel drug delivery technology, ENHANZE, for subcutaneous (SC) administration of drugs.

HALO sits at a Zacks Rank #3 (Hold), holds a Growth Style Score of B, and has a VGM Score of B. Earnings and sales are forecasted to increase 27.8% and 15.6% year-over-year, respectively.

Two analysts revised their earnings estimate higher in the last 60 days for fiscal 2024, while the Zacks Consensus Estimate has increased $0.02 to $3.54 per share. HALO also boasts an average earnings surprise of 5.3%.

Looking at cash flow, Halozyme Therapeutics is expected to report cash flow growth of 19.7% this year; HALO has generated cash flow growth of 48.7% over the past three to five years.

Investors should take the time to consider HALO for their portfolios due to its solid Zacks Rank rating, notable growth metrics, and impressive Growth and VGM Style Scores.

Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report

Halozyme Therapeutics, Inc. (HALO) : Free Stock Analysis Report

To read this article on Zacks.com click here.

Zacks Investment Research